Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Staphylococcal enterotoxin B is a potent bacterial superantigen exotoxin produced by Staphylococcus aureus. It acts as a virulence factor and is one of the primary toxins responsible for staphylococcal food poisoning in humans. Mechanistically, SEB binds directly to major histocompatibility complex class II molecule on antigen-presenting cells and cross-links them with T-cell receptors outside the normal antigen binding groove. This non-specific activation can stimulate up to 20% of T-cells simultaneously—far more than typical antigens—leading to massive cytokine release and systemic inflammation[1][5][6]. Clinically, exposure can result in food poisoning, toxic shock syndrome, atopic dermatitis, asthma exacerbations, and multi-organ failure at high doses[1][8]. There are currently no approved treatments or vaccines for SEB intoxication; however, monoclonal antibodies have shown promise in preclinical studies[1]. Due to its potency and stability (including resistance to heat), it has been studied as a potential biological weapon[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Staphylococcal enterotoxin B.